Cost advantages concentrated in higher OOP tiers: only 15% of all prescriptions were cheaper, but MCCPDC undercut insurance for ~82% of fills when OOP exceeded $15. Therapeutic areas with frequent ...
Swarup Kumar, MD, discusses how bispecific antibodies are pushing myeloma cure rates to 40%—and what clinicians must know ...
Formal adoption of PMOS replaces a cyst-centric label with terminology capturing endocrine, metabolic, and ovarian ...
Datopotamab deruxtecan is now a first-line targeted therapy for immunotherapy-ineligible metastatic TNBC, addressing the ~70% ...
Identification of fibroids on ultrasound can prematurely close evaluation, despite frequent co-existence and a ...
Young men and minority patients with early-onset CRC in urban areas face higher CVD death risk, challenging assumptions about ...
High co-payments for potentially curative cell and gene therapies create avoidable access barriers; value-based insurance design should eliminate patient cost sharing for these therapies. Cell and ...
GLP-1 receptor agonists are emerging as HF therapies, particularly for obesity-related HFpEF, via effects on weight, inflammation, and cardiometabolic stress. STEP-HFpEF demonstrated semaglutide ...
USPSTF recommendations have statutory coverage implications under the ACA, mandating no-cost coverage for graded preventive services and directly shaping access to mammography, colorectal screening, ...
Simple FNI labs pinpoint high‑mortality MASLD fibrosis in type 2 diabetes, challenging FIB‑4 and sharpening MASH liver ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results